Trial Outcomes & Findings for MetaNeb® Chest X-ray Study (NCT NCT02871258)

NCT ID: NCT02871258

Last Updated: 2024-09-24

Results Overview

Chest x-rays were scored using the Kelly scoring system to assess the presence of atelectasis on Day 2, after initiation of therapy with The MetaNeb® System. Scores for chest x-rays at Day 2 were compared to the scores for chest x-rays taken at baseline. 3 of the 8 subjects did not have measurable level of atelectasis at baseline and were excluded from the Kelly Score analyses. A score of 0 represents normal clear lungs whilst a score of 4 represent the whole lung is consolidated. A blinded reader scored each lung separately based on the Kelly Score scale. The Kelly scores from the left and right lung of each subject were averaged to get a mean score for each subject. Kelly Score ranges are as follows: 0 Normal; 1 Linear atelectasis; 1.25 a: one third of hemidiaphragm; 1.50b: two thirds of hemidiaphragm;1.75c: all of one hemidiaphragm; 2 Lobar consolidation; 3 Lobar collapse; 4 Bronchial consolidation (whole lung, bronchopneumonia etc.,)

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

8 participants

Primary outcome timeframe

Approximately 48 hours post-initiation of therapy with The MetaNeb® System.

Results posted on

2024-09-24

Participant Flow

Participant milestones

Participant milestones
Measure
The MetaNeb® System Treatment
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Overall Study
STARTED
8
Overall Study
COMPLETED
8
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

MetaNeb® Chest X-ray Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Age, Continuous
69.6 Years
STANDARD_DEVIATION 5.90 • n=99 Participants
Sex: Female, Male
Female
2 Participants
n=99 Participants
Sex: Female, Male
Male
6 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
Race (NIH/OMB)
White
7 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
BMI
28.18 kg/m^2
STANDARD_DEVIATION 3.271 • n=99 Participants
History of Asthma
Yes
0 Participants
n=99 Participants
History of Asthma
No
8 Participants
n=99 Participants
COPD
Yes
2 Participants
n=99 Participants
COPD
No
6 Participants
n=99 Participants
Obstructive Sleep Apnea
Yes
0 Participants
n=99 Participants
Obstructive Sleep Apnea
No
8 Participants
n=99 Participants
Other Pulmonary Condition
Yes
1 Participants
n=99 Participants
Other Pulmonary Condition
No
7 Participants
n=99 Participants
Bronchiectasis
Yes
0 Participants
n=99 Participants
Bronchiectasis
No
8 Participants
n=99 Participants
Neuromuscular disease
Yes
0 Participants
n=99 Participants
Neuromuscular disease
No
8 Participants
n=99 Participants
Cystic Fibrosis
Yes
0 Participants
n=99 Participants
Cystic Fibrosis
No
8 Participants
n=99 Participants

PRIMARY outcome

Timeframe: Approximately 48 hours post-initiation of therapy with The MetaNeb® System.

Chest x-rays were scored using the Kelly scoring system to assess the presence of atelectasis on Day 2, after initiation of therapy with The MetaNeb® System. Scores for chest x-rays at Day 2 were compared to the scores for chest x-rays taken at baseline. 3 of the 8 subjects did not have measurable level of atelectasis at baseline and were excluded from the Kelly Score analyses. A score of 0 represents normal clear lungs whilst a score of 4 represent the whole lung is consolidated. A blinded reader scored each lung separately based on the Kelly Score scale. The Kelly scores from the left and right lung of each subject were averaged to get a mean score for each subject. Kelly Score ranges are as follows: 0 Normal; 1 Linear atelectasis; 1.25 a: one third of hemidiaphragm; 1.50b: two thirds of hemidiaphragm;1.75c: all of one hemidiaphragm; 2 Lobar consolidation; 3 Lobar collapse; 4 Bronchial consolidation (whole lung, bronchopneumonia etc.,)

Outcome measures

Outcome measures
Measure
The MetaNeb® System Treatment
n=5 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 2 : Baseline Score
1.63 scores on a scale
Standard Deviation 0.18
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 2 : Day 2 Score
1.75 scores on a scale
Standard Deviation 0.35
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 4 : Baseline Score
1.25 scores on a scale
Standard Deviation 0.00
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 4 : Day 2 Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 5 : Baseline Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 5 : Day 2 Score
1.25 scores on a scale
Standard Deviation 0.0
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 6 : Baseline Score
0.75 scores on a scale
Standard Deviation 1.06
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 6 : Day 2 Score
1.25 scores on a scale
Standard Deviation 0.35
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 8 : Baseline Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 8 : Day 2 Score
0.63 scores on a scale
Standard Deviation 0.88

SECONDARY outcome

Timeframe: Approximately 24 hours and at Day 4, approximately 96 hours, or at discharge if discharge occurs before Day 4

Mean chest x-ray score change for both lungs at Day 1 (approx. 24 hours) and at Day 4 (approx. 96 hours or at discharge, if discharge occurs before Day 4) after initiation of therapy with The MetaNeb® System. Scored using the Kelly score, as described above, to assess the presence of atelectasis. 3 of the 8 subjects did not have measurable level of atelectasis at baseline and were excluded from the Kelly Score analyses. A score of 0 represents normal clear lungs whilst a score 4 represent the whole lung is consolidated. A blinded reader scored each lung separately based on the Kelly Score scale. The Kelly scores from the left and right lung of each subject were averaged to get a mean score for each subject. Kelly Score ranges are as follows: 0 Normal; 1 Linear atelectasis; 1.25 a: one third of hemidiaphragm; 1.50b: two thirds of hemidiaphragm;1.75c: all of one hemidiaphragm; 2 Lobar consolidation; 3 Lobar collapse; 4 Bronchial consolidation (whole lung, bronchopneumonia etc.,)

Outcome measures

Outcome measures
Measure
The MetaNeb® System Treatment
n=5 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 2: Baseline Score
1.63 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 2: Day 1 Score
1.75 scores on a scale
Standard Deviation 0.35
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 2: Day 4/Early Termination Score
1.25 scores on a scale
Standard Deviation 0.00
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 4: Baseline Score
1.25 scores on a scale
Standard Deviation 0.00
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 4: Day 1 Score
1.25 scores on a scale
Standard Deviation 0.00
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 4: Day 4/Early Termination Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 5: Baseline Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 5: Day 1 Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 5: Day 4/Early Termination Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 6: Baseline Score
0.75 scores on a scale
Standard Deviation 1.06
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 6: Day 1 Score
1.25 scores on a scale
Standard Deviation 0.35
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 6: Day 4/Early Termination Score
1.25 scores on a scale
Standard Deviation 0.35
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 8: Baseline Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 8: Day 1 Score
1.13 scores on a scale
Standard Deviation 0.18
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 8: Day 4/Early Termination Score
0.63 scores on a scale
Standard Deviation 0.88

SECONDARY outcome

Timeframe: Comparing baseline, Day 1, Day 2, and Day 4/discharge.

Chest x-ray improvement using a comparative scale after a minimum of forty-eight (48) hours of therapy with The MetaNeb® System. Chest x-ray improvement assessed using comparative scale for baseline, Day 1, Day 2, and Day 4/discharge. Four chest x-rays for each enrolled subject (baseline, Day 1, Day 2, and day 4/discharge), with date and time masked, were sent to the radiologist for comparison. The radiologist ranked the four x-rays as 1, 2, 3, or 4 (1 = least atelectasis, 4 = most atelectasis). \*Subjects 3 and 4 were discharged on Day 2, and therefore the Day 2 and Day 4/Early Discharge Chest X-rays are one in the same for the purposes of the analysis

Outcome measures

Outcome measures
Measure
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Day 1
4 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Baseline
4 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Day 1
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Day 2
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Day 4/Early Discharge
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Baseline
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Day 1
4 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Day 2
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Day 4/Early Discharge
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Baseline
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Day 1
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Day 2*
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Day 4/Early Discharge*
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Baseline
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Day 1
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Day 2*
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Day 4/Early Discharge*
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Baseline
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Day 2
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Day 4/Early Discharge
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Baseline
4 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Day 1
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Day 2
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Day 4/Early Discharge
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Baseline
1 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Day 1
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Day 2
4 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Day 4/Early Discharge
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Baseline
4 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Day 1
3 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Day 2
2 scores on a scale
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Day 4/Early Discharge
1 scores on a scale

SECONDARY outcome

Timeframe: Oxygenation Index (SpO2 /FiO2 ratio) at Baseline, Day 1 AM, Day 1 PM, Day 2 AM, Day 2 PM, and Day 4/early discharge

Oxygenation Index (SpO2 /FiO2 ratio) at Day 1, Day 2, and day 4/discharge compared to baseline. SPO2/FiO2 is available for only the 6 subjects that received oxygen during the study. Subjects 3 and 4 did not receive oxygen and no SPO2/FiO2 ratios were calculated. higher SPO2/FiO2 value indicates better oxygenation.

Outcome measures

Outcome measures
Measure
The MetaNeb® System Treatment
n=6 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 2 AM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Baseline
267 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 1 AM
275 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 1 PM
275 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 2 AM
278 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 2 PM
313 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 4/Early Discharge
275 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Baseline
218 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 1 AM
291 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 1 PM
300 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 2 AM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 2 PM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 4/Early Discharge
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Baseline
350 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 1 AM
357 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 1 PM
336 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 2 AM
354 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 2 PM
336 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 4/Early Discharge
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Baseline
269 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 1 AM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 1 PM
346 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 2 AM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 2 PM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 4/Early Discharge
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Baseline
309 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 1 AM
325 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 1 PM
400 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 2 AM
400 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 2 PM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 4/Early Discharge
350 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Baseline
350 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 1 AM
357 SPO2/FiO2 ratio
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 1 PM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 2 PM
NA SPO2/FiO2 ratio
Subject not on Oxygen.
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 4/Early Discharge
NA SPO2/FiO2 ratio
Subject not on Oxygen.

SECONDARY outcome

Timeframe: Patient reported level of dyspnea assessed by Modified Borg Dyspnea Scale on Baseline (Day 0), Day 1, and Day 2.

Patient reported level of dyspnea (assessed by Modified Borg Dyspnea Scale).This is a scale that asks patients to rate the difficulty of their breathing. It starts at number zero (0) where the breathing is causing the patient no difficulty at all, and progresses through to number ten (10) where the patients' breathing difficulty is maximal. 0: Nothing at all; 0.5: Very, very slight (just noticeable); 1: Very slight; 2: Slight; 3: Moderate; 4: Somewhat severe; 5: Severe; 7: Very severe; 9: Very, very severe (almost maximal); 10: Maximal.

Outcome measures

Outcome measures
Measure
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Patient Reported Level of Dyspnea Assessed by Modified Borg Dyspnea Scale.
Mean Score at Baseline
3.5 scores on a scale
Standard Deviation 1.31
Patient Reported Level of Dyspnea Assessed by Modified Borg Dyspnea Scale.
Mean Score at Day 1
3.25 scores on a scale
Standard Deviation 1.58
Patient Reported Level of Dyspnea Assessed by Modified Borg Dyspnea Scale.
Mean Score at Day 2
1.94 scores on a scale
Standard Deviation 1.15

SECONDARY outcome

Timeframe: Respiratory status evaluation at time of enrollment and on Day 2

Change in patient respiratory status (Respiratory Status Evaluation). Physician observation and evaluation of patient respiratory status at time of enrollment (baseline) and on Day 2 to assess if worse, unchanged, or improved through: * Lung assessment: percussion * Lung assessment: Auscultation * Cough assessment * Secretion assessment * oxygenation * Work of breathing * Other observations: General appearance, mental acuity, respiratory pain

Outcome measures

Outcome measures
Measure
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment. The MetaNeb® System
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Secretion Assessment · Improved
6 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Secretion Assessment · Unchanged
2 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Percussion · Improved
7 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Percussion · Unchanged
1 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Percussion · Worse
0 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Auscultation · Improved
7 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Auscultation · Unchanged
1 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Auscultation · Worse
0 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Cough Assessment · Improved
7 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Cough Assessment · Unchanged
1 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Cough Assessment · Worse
0 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Secretion Assessment · Worse
0 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Oxygenation · Improved
6 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Oxygenation · Unchanged
2 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Oxygenation · Worse
0 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Work of Breathing · Improved
5 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Work of Breathing · Unchanged
3 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Work of Breathing · Worse
0 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Other Observations (General Appearance, Mental Acuity, Respiratory Pain) · Improved
7 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Other Observations (General Appearance, Mental Acuity, Respiratory Pain) · Unchanged
1 Participants
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Other Observations (General Appearance, Mental Acuity, Respiratory Pain) · Worse
0 Participants

Adverse Events

The MetaNeb® System Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Baxter Clinical Trials Disclosure Call Center

Baxter Healthcare

Phone: (224) 948-7359

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place